ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1764

Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1

Clayton Sontheimer1 and Keith B. Elkon2, 1Pediatric Rheumatology, University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cutaneous lupus and innate immunity, Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Animal Models Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions show local Type 1 Interferon (IFN-I) profiles similar to that seen in the blood. The pathogenic effect of ultraviolet light (UV) in SLE stands in contrast to the immunosuppressive effects of UV in the normal host, and UV light is used to treat various skin diseases such as psoriasis. Differences in the mechanisms linking UV light to immune suppression versus inflammation and cutaneous flares of lupus are not well understood. Here, we asked whether, and under what conditions, repetitive UVB-exposure induces IFN-I and examined what its biological effects were in the skin in the normal host.

Methods:

Shaved C57BL/6 (B6) and IFNAR KO (B6 background) mice were irradiated with narrowband UVB at 100 mJ/cm2/day for 5 consecutive days. To inhibit idoleamine 2,3-dioxygenase 1 (IDO1) in vivo,1-Methyl-d-tryptophan (1-MT) was added to drinking water (2 mg/mL) and fed to mice ad libitumbeginning 3 days prior to irradiation until experiment end. Serial punch biopsies (6 mm) were obtained at 3, 24, and 72 hrs following UVB exposure. Skin immune cell populations were analyzed by flow cytometry using CD45, CD11b, Ly6C, Ly6G, MHC II, CD64, and CD3. Skin samples were examined for mRNA expression by QPCR of pro-inflammatory cytokines and Interferon Stimulated Genes (ISG), and skin samples were analyzed histologically by H&E and for IDO1 expression by immunofluorescence

Results:

Repeated UVB exposure in normal wild-type B6 mice induced a modest IFN-I skin response with bimodal peaks at 3 and 72 hrs when compared to mice receiving a single UVB dose and non-irradiated control mice. Surprisingly, UVB-irradiated IFNAR KO mice that were unable to respond to IFN-I, had increased levels of pro-inflammatory cytokines such as TNF and IL-6 at 3 and 24 hr time points and had increased levels of inflammation by pathology scores. These findings suggest a protective role for IFN-I. Since IDO1 is an ISG and a potent suppressor of inflammation, we examined IDO1 expression following UVB. Significantly, UVB induced expression of IDO1 in the skin in B6 but not IFNAR KO mice. Consistent with this finding, inhibition of IDO1 by 1-MT treatment in B6 mice caused increased cellular infiltration, worsened histologic appearance, and increased pro-inflammatory cytokines similar to that seen in IFNAR KO mice. Infiltrating dendritic cells in IDO1-inhibited mice had decreased IL-10 levels compared to B6 mice. IDO1 inhibition in IFNAR KO mice did not alter UVB-induced inflammation consistent with IFN-I and IDO1 being in the same pathway.

Conclusion:

In the normal host, repeated doses of UVB induces an IFN-I response in the skin that attenuates pro-inflammatory signals and limits cellular recruitment. Immunosuppression is at least in part mediated though expression and activity of IDO1. This establishes a unique role for IFN-induced IDO1 in promoting the protective effects of UVB in healthy individuals. Loss of this pathway may contribute to the enhanced UVB response as observed in lupus photosensitivity.


Disclosure: C. Sontheimer, None; K. B. Elkon, None.

To cite this abstract in AMA style:

Sontheimer C, Elkon KB. Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1 [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/type-1-interferon-in-the-skin-stimulated-by-ultraviolet-b-light-generates-immune-suppression-mediated-by-idoleamine-23-dioxygenase-1/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-1-interferon-in-the-skin-stimulated-by-ultraviolet-b-light-generates-immune-suppression-mediated-by-idoleamine-23-dioxygenase-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology